Table 1. Summary of anesthesia and treatment protocols.
| Anesthetic agent (application route) | Respiratory conditions | Animals | Initial (priming) dose | Maintenance dose | Challenge | |
|---|---|---|---|---|---|---|
| Isoflurane (Inhalation) | Spontaneously breathing (carrier gas composed of oxygen and air, 1:5 v/v) | rat | Sprague Dawley | 4% | 2.0–2.3% | Acetazolamide (30 mg/kg) |
| mouse | C57BL/6J | 2–3% | 1.8–2.0% | Acetazolamide (30 mg/kg) Olanzapine (3 mg/kg; C57BL/6J mice) | ||
| BTBR T+tf/J | ||||||
| CD1 | ||||||
| Medetomidinea(s.c.) | rat | Sprague Dawley | 0.2 mg/kg (+4% isoflurane) | 0.1 mg/kg/h | Acetazolamide (30 mg/kg) | |
| mouse | C57BL/6J | 0.3 mg/kg (+2.5–3% isoflurane) | 0.6 mg/kg/h | Acetazolamide (30 mg/kg) Olanzapine (3 mg/kg) | ||
| Etomidateb(i.v.) | rat | Sprague Dawley | 5 mg/kg/min (3 min) (+4% isoflurane) | 0.25 mg/kg/min | Acetazolamide (30 mg/kg) | |
| mouse | C57BL/6J | 4 mg/kg/min (3 min) (+2.5–3% isoflurane) | 0.75 mg/kg/min | Acetazolamide (30 mg/kg) Olanzapine (3 mg/kg; C57BL/6J mice) Electrical hindpaw stimulation (2 mA; ventilated C57BL/6J mice) | ||
| BTBR T+tf/J | 1.0 mg/kg/min | |||||
| CD1 | 1.5 mg/kg/min | |||||
ai.v., intravenous.
bs.c., subcutaneous.